Abbott’s PROGRESS Study of Kaletra and Isentress Compared With a Standard HIV Regimen Meets the Pre-Specified Primary …

Abbott’s PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary …
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor , Kaletra® , and Merck’s integrase inhibitor, Isentress® , to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors in Truvada® in antiretroviral-naive adult patients.  Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS study.  …
Read more on PR Newswire via Yahoo! Finance